XNASXAIR
Market cap27mUSD
Jan 17, Last price
0.38USD
1D
1.55%
1Q
13.03%
Jan 2017
-98.73%
IPO
-93.54%
Name
Beyond Air Inc
Chart & Performance
P/E
—
P/S
23.67
EPS
—
Div Yield, %
%
Shrs. gr., 5y
31.30%
Rev. gr., 5y
-31.57%
Revenues
1m
Net income
-60m
L+7.93%
CFO
-56m
L+69.69%
Earnings
Feb 10, 2025
Profile
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑12 | 2016‑12 | 2016‑06 | 2015‑06 | |
| Income | |||||||||||
Revenues | 1,159 | ||||||||||
Cost of revenue | 64,166 | 52,059 | 30,798 | ||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | (63,007) | (52,059) | (30,798) | ||||||||
NOPBT Margin | |||||||||||
Operating Taxes | (3,555) | (108) | |||||||||
Tax Rate | |||||||||||
NOPAT | (63,007) | (48,504) | (30,690) | ||||||||
Net income | (60,242) 7.93% | (55,816) 29.27% | (43,177) 88.75% | ||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | 27,967 | 3,705 | 72,827 | ||||||||
BB yield | -48.47% | -1.83% | -42.47% | ||||||||
| Debt | |||||||||||
Debt current | 1,636 | 1,151 | 1,208 | ||||||||
Long-term debt | 18,935 | 5,138 | 4,639 | ||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | 1,589 | 4,500 | 7,999 | ||||||||
Net debt | (13,897) | (39,593) | (74,395) | ||||||||
| Cash flow | |||||||||||
Cash from operating activities | (56,014) | (33,009) | (23,134) | ||||||||
CAPEX | (5,745) | (3,877) | (1,449) | ||||||||
Cash from investing activities | (12,235) | (20,587) | (1,450) | ||||||||
Cash from financing activities | 43,167 | 2,696 | 79,450 | ||||||||
FCF | (66,996) | (51,790) | (32,111) | ||||||||
| Balance | |||||||||||
Cash | 34,468 | 45,882 | 80,242 | ||||||||
Long term investments | |||||||||||
Excess cash | 34,410 | 45,882 | 80,242 | ||||||||
Stockholders' equity | (237,569) | (175,286) | (118,035) | ||||||||
Invested Capital | 284,599 | 208,792 | 207,730 | ||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | 33,160 | 29,974 | 25,668 | ||||||||
Price | 1.74 -74.22% | 6.75 1.05% | 6.68 21.45% | ||||||||
Market cap | 57,699 -71.48% | 202,322 18.00% | 171,464 73.15% | ||||||||
EV | 45,940 | 166,842 | 102,574 | ||||||||
EBITDA | (60,655) | (50,889) | (30,210) | ||||||||
EV/EBITDA | |||||||||||
Interest | 2,912 | 30 | 775 | ||||||||
Interest/NOPBT | |||||||||||